Clinical pharmacologist Matthias Schwab is a new member of the Academia Europaea

Hinweis zur Verwendung von Bildmaterial: Die Verwendung des Bildmaterials zur Pressemitteilung ist bei Nennung der Quelle vergütungsfrei gestattet. Das Bildmaterial darf nur in Zusammenhang mit dem Inhalt dieser Pressemitteilung verwendet werden. Falls Sie das Bild in höherer Auflösung benötigen oder Rückfragen zur Weiterverwendung haben, wenden Sie sich bitte direkt an die Pressestelle, die es veröffentlicht hat.

Matthias Schwab is a new member of the Academia Europaea science academy | Copyright: ©Björn Hänssler for Bosch Health Campus | Download

Prof. Dr. Matthias Schwab, the head of Dr. Margarete Fischer-Bosch-Institute for Clinical Pharmacology (IKP) at the Bosch Health Campus, has been elected as a full member of the renowned Academia Europaea science academy. He is a member of the “Clinical & Veterinary Science” section.

The Academia Europaea was founded in 1988 as a non-governmental science academy in London. Today it has around 5,000 members from the fields of physics and technology, life sciences and medicine, mathematics, humanities, social and cognitive sciences, economics and law. Among them are also 83 Nobel Prize winners.

Highest possible standards in science, research and education

The academy pursues the goals of setting the highest possible standards in science, research and education, identifying trans-European research topics and thus promoting better understanding of scientific issues among the public. Acceptance is subject exclusively to personal nomination and subsequent election by the Academy Council. “I am very happy about this European award, which expresses international perception of the scientific contributions of the Institute of Clinical Pharmacology”, says Prof. Dr. Matthias Schwab about his appointment.

Prof. Dr. Matthias Schwab has been heading the IKP since 2007. Furthermore, he is Medical Director of the Department of Clinical Pharmacology at the University Hospital in Tübingen and Chair of this subject at Tübingen University. The key area of his work is pharmacological genome research and its significance for personalised medicine. Matthias Schwab has been a full member of the Academy of Sciences and Literature Mainz already since 2012, and a member of the National Academy of Sciences Leopoldina since 2014.

Further information
https://www.bosch-health-campus.de/en

Contact
Bosch Health Campus
Corporate Communications
Cornelia Varwig
presse@bosch-health-campus.com

The Dr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie (IKP)

The Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology (IKP) is a research institute at the Bosch Health Campus of the Robert Bosch Stiftung. It is one of the largest scientific research institutes in the field of clinical pharmacology in Germany.

The mission of IKP is to enable precision medicine by improving drug therapy with state-of-the-art technologies and novel methods. Its goal is to transfer scientific findings from bench to bedside and work towards innovations on how diseases, in particular cancer, will be treated in the 21st century. Therefore, the institute collaborates closely with clinical research groups at the Robert Bosch Hospital and international partners.

The IKP was established in 1973 with a generous donation by Dr. Margarete Fischer-Bosch, the eldest daughter of the entrepreneur Robert Bosch. Since then, the Robert Bosch Stiftung has provided the main financial support. In addition, the institute receives significant external funding.

The Bosch Health Campus combines all of the Robert Bosch Stiftung's institutions and funding activities in the field of health: the Robert Bosch Hospital, the Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, the Robert Bosch Center for Tumor Diseases, the Institute for the History of Medicine, the Irmgard Bosch Learning Center, and the Robert Bosch Center for Innovative Health.